Filing summary
Company: Eton Pharmaceuticals, Inc. (NASDAQ: ETON). Filing: Form 8-K, filed September 28, 2026. This is an event filing, not a periodic financial report.
Business context and event
On September 28, 2026, Eton announced the launch of IMPAVIDO (miltefosine) capsules. The company said it integrated Eton Cares patient support, including a $0 co-pay for eligible commercially insured patients and expanded patient assistance programs. The press release is identified as Exhibit 99.1 but its full text is not included in the supplied filing content.
Financial results and changes
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics. It does not quantify the launch’s expected financial impact or provide a prior-period comparison.
Outlook, risks, and contingencies
No guidance, forecast, management commentary beyond the launch announcement, or specific risks and contingencies are disclosed in the supplied text.
Important facts to verify
- Review Exhibit 99.1 for additional product, launch, and commercial details.
- Verify product availability, eligible-patient criteria, and terms of the Eton Cares support programs.
- Look for subsequent disclosures quantifying launch-related sales, costs, or expectations.